Feed HEPA
HE

Hepion Pharmaceuticals, Inc.

HEPA · OTC

$0.08 +7.18% (+$0.01)
1M +26.07%
Market Cap $835.4K
P/E Ratio -
Div. Yield -
ROE 139.73%
Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 0.65x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 62.32%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 219.39%
ROE 139.73%
ROA 165.42%
Debt
69 /100
Low
Debt/Equity 0.00x
Current ratio 3.91x
Int. coverage -124.87x
Stability
19 /100
Unstable
Beta 1.76x
EPS volatility 55.17%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about HEPA
Online

About the company

Hepion Pharmaceuticals, Inc. (HEPA) is a biotechnology company focused on the research and development of therapies for liver diseases and metabolic disorders. Headquartered in the United States, the company aims to utilize its drug candidates to treat diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepion Pharmaceuticals seeks to develop innovative pharmaceutical solutions for patients with these serious health conditions. Shares of Hepion Pharmaceuticals, Inc. (HEPA), listed on the NASDAQ, can be an appealing choice for investors seeking investment opportunities in the biotechnology and liver disease treatment sector.

Sector

Healthcare

Industry

Biotechnology

CEO

Gary S. Stetz

Employees

2

Headquarters

Morristown

Upcoming events

14 OCT

Earnings

Upcoming earnings report

25d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.